Information Provided By:
Fly News Breaks for June 11, 2019
Jun 11, 2019 | 05:54 EDT
Barclays analyst Balaji Prasad started Foamix Pharmaceuticals with an Overweight rating and $10 price target. The analyst launched coverage of 20 U.S. Specialty Pharmaceuticals with a Neutral industry view. He placed importance on cash flows and companies' ability to manage leverage and improve balance sheets.
News For FOMX From the Last 2 Days
There are no results for your query FOMX